Gain Therapeutics Inc

For the period ended Jun 30, 2024. Filed Aug 8, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 8, 2024

GANX$1.08-0.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets (Unaudited)

CONDENSED CONSOLIDATED BALANCE SHEETS


· June 30, · December 31,
· · · 2024 · · 2023
Assets · ·
Current assets: · ·
Cash and cash equivalents	$16,936,315	$11,794,949
Marketable securities - current	—	4,999,704
Tax credits	313,248	242,577
Prepaid expenses and other current assets	1,289,316	741,638
Total current assets	$18,538,879	$17,778,868

Non-current assets:
Property and equipment, net	$123,930	$125,962
Internal-use software	158,149	193,375
Operating lease - right of use assets	325,879	459,215
Restricted cash	31,803	34,021
Long-term deposits and other non-current assets	17,547	17,890
Total non-current assets	657,308	830,463
Total assets	$19,196,187	$18,609,331

Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$2,046,832	$1,318,965
Operating lease liability - current	186,846	229,693
Other current liabilities	3,468,254	2,160,366
Deferred income - current	710,001	1,122,138
Loans - current	111,051	118,797
Total current liabilities	$6,522,984	$4,949,959

Non-current liabilities:
Defined benefit pension plan	$298,428	$307,454
Operating lease liability - non-current	134,321	229,855
Deferred income - non-current	80,364	94,786
Loans - non-current	375,352	449,053
Total non-current liabilities	888,465	1,081,148
Total liabilities	$7,411,449	$6,031,107

Stockholders’ equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; nil shares issued and outstanding as of June 30, 2024 and December 31, 2023.	—	—
Common stock, $0.0001 par value: 50,000,000 shares authorized; 25,172,573 issued and outstanding as of June 30, 2024; 16,206,680 issued and outstanding as of December 31, 2023.	2,518	1,621
Additional paid-in capital	84,710,747	73,113,079
Accumulated other comprehensive income	12,462	247,241
Accumulated deficit	(60,783,717)	(38,516,197)
Loss for the period	(12,157,272)	(22,267,520)
Total stockholders’ equity	11,784,738	12,578,224
Total liabilities and stockholders’ equity	$19,196,187	$18,609,331

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.